Dae Young Zang

Second Affiliated Hospital of Dalian Medical University — China

Medicine · Health Sciences

36h-index12.7kcitations308works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(92), Colorectal Cancer Treatments and Studies(77), Chronic Myeloid Leukemia Treatments(65), Chronic Lymphocytic Leukemia Research(56), Lung Cancer Treatments and Mutations(44)

Publications307 total

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer
British Journal of Cancer·2025Open Access
EP.13.07 Association of Gut Microbiota and Metabolites With Thalidomide-Induced Antiemetic Efficacy in Small Cell Lung Cancer Patients
Journal of Thoracic Oncology·2025
P3.03.35 Association of Intestinal Flora and Metabolites With Bone Metastasis in Patients With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
P1.07.57 Alterations in the Gut Microbiota and Metabolites in Patients With Liver Injury Induced by Third-Generation EGFR-Targeted Drugs
Journal of Thoracic Oncology·2025
Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia
International Journal of Molecular Sciences·2025Open Access
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
Journal of Clinical Oncology·2025
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial
Cancer Research and Treatment·2024Open Access
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes
Cancer Research and Treatment·2024· 1 citedOpen Access
Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity
Molecular and Cellular Biochemistry·2024· 4 citedOpen Access
Pharmacokinetics of Vancomycin in Healthy Korean Volunteers and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients with Normal Renal Function
Antibiotics·2024Open Access
P1.06B.19 Effect of Gut Microbiota and Metabolites on Malignant Pleural Effusion of Lung Adenocarcinoma
Journal of Thoracic Oncology·2024Open Access
P1.03E.01 Effect of Gut Microbiota and Metabolites on the Efficacy of Immunotherapy Combined with Chemotherapy in Lung Squamous Cell Carcinoma Patients
Journal of Thoracic Oncology·2024Open Access
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
ESMO Open·2024· 2 citedOpen Access
<scp>FDA</scp> regulatory considerations for oncology drug development
Pharmacology Research & Perspectives·2024· 5 citedOpen Access
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY
Journal of Clinical Oncology·2024· 34 cited
Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
Leukemia Research·2024· 2 cited
446P A prospective study for real-world data (RWD) of ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KCSG ST21-06)
Annals of Oncology·2024Open Access
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22–09
BMC Cancer·2024· 6 citedOpen Access
Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Cancer Research and Treatment·2024· 3 citedOpen Access
Abstract CT216: Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression
Cancer Research·2024· 1 cited
page 1 of 16Next →

Frequent Co-authors

Sun Young Rha(9), Yoon‐Koo Kang(7), Y. Choi(7), In Gyu Hwang(7), Hawk Kim(7), Dong‐Hoe Koo(7), Min‐Hee Ryu(6), Keun‐Wook Lee(6), Joon Oh Park(6), Jinny Park(6), Jung Han Kim(6), Hyeong Su Kim(6), Jeong Hwan Yook(5), Sang Cheul Oh(5), Yeul Hong Kim(5), Myung Soo Hyun(5), Joo Seop Chung(5), Minkyu Jung(5), Woo Kyun Bae(5), Baek‐Yeol Ryoo(4)